在Journal of Hematology & Oncology上发表了题为Safe and effective off‑the‑shelf immunotherapy based on CAR.CD123‑NK cells for the treatment of acute myeloid leukaemia的文章,提出了一种基于自然杀伤(natural killer, NK)细胞的即用型(off-the-shelf)疗法,并在体外实验及小鼠模型中证实了该疗法的安...
实验表明,GD2 - CAR NK - 92 细胞对 SK - N - LO 和 LAN - 1 细胞的裂解作用比野生型 NK - 92 细胞显著增强,但 TIGIT-/-GD2 - CAR NK - 92 细胞与 GD2 - CAR NK - 92 细胞相比,细胞毒性没有显著增强。脱颗粒和干扰素 - γ 释放实验也证实,只有 GD2 - CAR NK - 92 细胞在与 SK - N -...
在EOC治疗的创新研究中,丹娜法伯癌症研究所的研究人员发现,他们改造后的记忆样NK细胞(cytokine-induced memory-like NK cell,CIML NK)不仅在体外实验中展现出卓越的抗肿瘤活性,而且在体内模型中也显著抑制了肿瘤生长和转移。这项研究成果发表在《Science Advances》杂志上,论文标题为“CAR memory–like NK cells ...
促进调节性T细胞(regulatory T cells,Tregs)的募集、抑制树突细胞(dendritic cell,DCs)和自然杀伤(natural killer,NK)细胞的功能等;另一方面,GBM细胞可以通过自身表达免疫抑制性分子,如程序性死亡因子1(programmed death 1,PD-1)的配体,从而抑制T细胞的活化和增殖[3]。
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany Article Open access 22 March 2021 References Stancovski, I. et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151, 6577–6582 (1993). CA...
我相信以细胞为基础的疗法,如CAR-T、 CAR-NK将发挥积极的作用。在未来的几年内,我们将看到与TCR和NK细胞信号有关的与众不同的治疗手段,期待着使用基因组编辑或iPSC技术进行某种通用细胞的大规模生产,此外还有更多基于大数据分析的结果,可以为我们筛...
The difference of the second- and third-generation CAR over the first-generation one is the addition of one and two co-stimulatory signaling domains. In the FDA-approved CAR T cells, these co-stimulatory domains are usually CD28 or 4-1BB. In CAR NK and CAR macrophage, their specific or ...
The limitations of generating an autologous cell product and the challenges of toxicity with CAR-T cells underscore the need to develop novel cell therapy products that are universal, safe, and potent. Natural killer (NK) cells are part of the innate immune system with unique advantages, ...
1) [4]. Considering the principles, an antigen expressed on the cell surface can be targeted by a CAR and varied T cell subsets, T cell progenitors, and other immune cells, in particular, natural killer (NK) cells, can be targeted by a CAR [5]. The establishment of the immune ...
seems to be a good candidate for CAR-immune cell therapy is the Natural Killer-T (NKT) cell. NKT cells have multiple features that make them potent cells against tumors and would be a powerful replacement for T cells and natural killer (NK) cells. NKT cells are cytotoxic immune cells ...